Cargando…
Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706250/ https://www.ncbi.nlm.nih.gov/pubmed/26735530 http://dx.doi.org/10.1097/MD.0000000000002236 |
_version_ | 1782409137662984192 |
---|---|
author | Lee, Jae-Hoon Kang, Jeonghyun Baik, Seung Hyuk Lee, Kang Young Lim, Beom Jin Jeon, Tae Joo Ryu, Young Hoon Sohn, Seung-Kook |
author_facet | Lee, Jae-Hoon Kang, Jeonghyun Baik, Seung Hyuk Lee, Kang Young Lim, Beom Jin Jeon, Tae Joo Ryu, Young Hoon Sohn, Seung-Kook |
author_sort | Lee, Jae-Hoon |
collection | PubMed |
description | To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate their variability depending on C-reactive protein (CRP) levels. In total, 179 CRC patients who underwent PET/CT scans before curative resection and KRAS mutation evaluation following surgery were enrolled. Maximum standardized uptake value (SUV(max)), peak standardized uptake value (SUV(peak)), metabolic tumor volume, and total lesion glycolysis were determined semiquantitatively. Associations between clinicopathologic and PET/CT-related parameters and KRAS expression were analyzed. Elevated CRP (>6.0 mg/L; n = 47) was associated with higher primary tumor size, higher SUV(max), SUV(peak), metabolic tumor volume, and total lesion glycolysis, compared with those for the group with a CRP lower than that the cutoff value (<6.0 mg/L; n = 132). Interestingly, the CRC patients (having CRP < 6.0 mg/L) with KRAS mutations had significantly higher (P < 0.05) SUV(max) and SUV(peak) values than the patients expressing wild-type KRAS mutations. Multivariate analysis revealed SUV(max) and SUV(peak) to be significantly associated with KRAS mutations (odds ratio = 3.3, P = 0.005, and odds ratio = 3.9, P = 0.004), together with histologic grade and lymph node metastasis. (18)F-FDG uptake was significantly higher in CRC patients with KRAS mutations and with normal CRP levels. A severe local inflammation with raised CRP levels, however, might affect accurate (18)F-FDG quantification in CRC tumors. Positron emission tomography/computed tomography-related parameters could supplement genomic analysis to determine KRAS expression in CRC; however, care should be exercised to guarantee proper patient selection. |
format | Online Article Text |
id | pubmed-4706250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-47062502016-01-19 Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level Lee, Jae-Hoon Kang, Jeonghyun Baik, Seung Hyuk Lee, Kang Young Lim, Beom Jin Jeon, Tae Joo Ryu, Young Hoon Sohn, Seung-Kook Medicine (Baltimore) 5307 To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate their variability depending on C-reactive protein (CRP) levels. In total, 179 CRC patients who underwent PET/CT scans before curative resection and KRAS mutation evaluation following surgery were enrolled. Maximum standardized uptake value (SUV(max)), peak standardized uptake value (SUV(peak)), metabolic tumor volume, and total lesion glycolysis were determined semiquantitatively. Associations between clinicopathologic and PET/CT-related parameters and KRAS expression were analyzed. Elevated CRP (>6.0 mg/L; n = 47) was associated with higher primary tumor size, higher SUV(max), SUV(peak), metabolic tumor volume, and total lesion glycolysis, compared with those for the group with a CRP lower than that the cutoff value (<6.0 mg/L; n = 132). Interestingly, the CRC patients (having CRP < 6.0 mg/L) with KRAS mutations had significantly higher (P < 0.05) SUV(max) and SUV(peak) values than the patients expressing wild-type KRAS mutations. Multivariate analysis revealed SUV(max) and SUV(peak) to be significantly associated with KRAS mutations (odds ratio = 3.3, P = 0.005, and odds ratio = 3.9, P = 0.004), together with histologic grade and lymph node metastasis. (18)F-FDG uptake was significantly higher in CRC patients with KRAS mutations and with normal CRP levels. A severe local inflammation with raised CRP levels, however, might affect accurate (18)F-FDG quantification in CRC tumors. Positron emission tomography/computed tomography-related parameters could supplement genomic analysis to determine KRAS expression in CRC; however, care should be exercised to guarantee proper patient selection. Wolters Kluwer Health 2016-01-08 /pmc/articles/PMC4706250/ /pubmed/26735530 http://dx.doi.org/10.1097/MD.0000000000002236 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0 |
spellingShingle | 5307 Lee, Jae-Hoon Kang, Jeonghyun Baik, Seung Hyuk Lee, Kang Young Lim, Beom Jin Jeon, Tae Joo Ryu, Young Hoon Sohn, Seung-Kook Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level |
title | Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level |
title_full | Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level |
title_fullStr | Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level |
title_full_unstemmed | Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level |
title_short | Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level |
title_sort | relationship between (18)f-fluorodeoxyglucose uptake and v-ki-ras2 kirsten rat sarcoma viral oncogene homolog mutation in colorectal cancer patients: variability depending on c-reactive protein level |
topic | 5307 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706250/ https://www.ncbi.nlm.nih.gov/pubmed/26735530 http://dx.doi.org/10.1097/MD.0000000000002236 |
work_keys_str_mv | AT leejaehoon relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel AT kangjeonghyun relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel AT baikseunghyuk relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel AT leekangyoung relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel AT limbeomjin relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel AT jeontaejoo relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel AT ryuyounghoon relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel AT sohnseungkook relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel |